JP5591112B2 - オリタバンシンの投与によってクロストリジウム・ディフィシレを抑制する方法 - Google Patents

オリタバンシンの投与によってクロストリジウム・ディフィシレを抑制する方法 Download PDF

Info

Publication number
JP5591112B2
JP5591112B2 JP2010524973A JP2010524973A JP5591112B2 JP 5591112 B2 JP5591112 B2 JP 5591112B2 JP 2010524973 A JP2010524973 A JP 2010524973A JP 2010524973 A JP2010524973 A JP 2010524973A JP 5591112 B2 JP5591112 B2 JP 5591112B2
Authority
JP
Japan
Prior art keywords
clostridium difficile
oritavancin
spores
glycopeptide antibiotic
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2010524973A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010539179A (ja
JP2010539179A5 (OSRAM
Inventor
マーク ハーヴェイ ウィルコックス
サイモン ベインズ
ダリオ ルウー
トーマス アール． パー
Original Assignee
ターガンタ セラピューティクス コーポレイション
ザ メディシンズ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ターガンタ セラピューティクス コーポレイション, ザ メディシンズ カンパニー filed Critical ターガンタ セラピューティクス コーポレイション
Publication of JP2010539179A publication Critical patent/JP2010539179A/ja
Publication of JP2010539179A5 publication Critical patent/JP2010539179A5/ja
Application granted granted Critical
Publication of JP5591112B2 publication Critical patent/JP5591112B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Zoology (AREA)
  • Dentistry (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010524973A 2007-09-12 2008-09-11 オリタバンシンの投与によってクロストリジウム・ディフィシレを抑制する方法 Active JP5591112B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97176607P 2007-09-12 2007-09-12
US60/971,766 2007-09-12
PCT/US2008/075949 WO2009036121A1 (en) 2007-09-12 2008-09-11 Method of inhibiting clostridium difficile by administration of oritavancin

Publications (3)

Publication Number Publication Date
JP2010539179A JP2010539179A (ja) 2010-12-16
JP2010539179A5 JP2010539179A5 (OSRAM) 2013-09-12
JP5591112B2 true JP5591112B2 (ja) 2014-09-17

Family

ID=40452464

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010524973A Active JP5591112B2 (ja) 2007-09-12 2008-09-11 オリタバンシンの投与によってクロストリジウム・ディフィシレを抑制する方法

Country Status (9)

Country Link
US (3) US8518873B2 (OSRAM)
EP (1) EP2195004B1 (OSRAM)
JP (1) JP5591112B2 (OSRAM)
CN (1) CN102316885A (OSRAM)
AU (1) AU2008298987B2 (OSRAM)
CA (1) CA2699550C (OSRAM)
EA (1) EA017564B1 (OSRAM)
ES (1) ES2535928T3 (OSRAM)
WO (1) WO2009036121A1 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8518873B2 (en) * 2007-09-12 2013-08-27 The Medicines Company Method of inhibiting clostridium difficile by administration of oritavancin
ES2884673T3 (es) * 2008-04-08 2021-12-10 Melinta Therapeutics Inc Oritavancina para inhibir y tratar biopelículas
AU2010245097B2 (en) 2009-04-28 2015-08-13 Melinta Therapeutics, Inc. Methods of treating bacterial infections using oritavancin
JP5986416B2 (ja) * 2012-04-11 2016-09-06 花王株式会社 皮膚外用剤
EP4233545A3 (en) 2012-11-23 2023-10-18 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
HK1218559A1 (zh) * 2013-02-04 2017-02-24 Seres Therapeutics, Inc. 抑制致病细菌生长的配方和方法
HK1218560A1 (zh) 2013-02-04 2017-02-24 Seres Therapeutics, Inc. 组成与方法
HK1220326A1 (zh) 2013-03-15 2017-05-05 Seres Therapeutics, Inc. 基於网络微生物组成和方法
PT3074027T (pt) 2013-11-25 2025-03-20 Nestle Sa Composições bacterianas sinérgicas e métodos de produção e utilização das mesmas
EP3082431A4 (en) 2013-12-16 2017-11-15 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
US10191380B2 (en) * 2014-10-14 2019-01-29 Az Electronic Materials (Luxembourg) S.A.R.L. Composition for resist patterning and method for forming pattern using same
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
AU2017221435A1 (en) * 2016-02-18 2018-09-06 Melinta Therapeutics, Inc. Oritavancin formulations
CN107325159A (zh) * 2016-04-29 2017-11-07 中国科学院上海药物研究所 一类万古霉素衍生物、其制备方法、药物组合物和用途
MX388732B (es) 2016-05-09 2025-03-20 Xellia Pharmaceuticals Aps Formulaciones de antibioticos glicopeptidicos estabilizados
US11701394B2 (en) 2017-08-14 2023-07-18 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
KR20200079292A (ko) 2017-10-30 2020-07-02 세레스 테라퓨틱스, 인코포레이티드 항생제 내성을 치료하기 위한 조성물 및 방법
WO2020035720A1 (en) * 2018-08-17 2020-02-20 Universidad Andrés Bello Method and pharmacological composition for the prevention of recurrent infections caused by clostridium difficile.
KR102444119B1 (ko) * 2020-04-22 2022-09-16 주식회사 인트론바이오테크놀로지 클로스트리디오이데스 디피실리 균에 대하여 용균 활성을 갖는 항균단백질 cdl200

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2961184B2 (ja) * 1990-05-07 1999-10-12 ミヤリサン株式会社 クロストリジウム・ディフィシル下痢症および偽膜性大腸炎の予防ならびに治療用医薬組成物
GB0212622D0 (en) * 2002-05-31 2002-07-10 Natural Technologies Group Ltd Bacterial transforming agent
AU2003240545A1 (en) * 2002-06-06 2003-12-22 Therapeutics Corporation Genome Use of ramoplanin to treat diseases associated with the use of antibiotics
TW200500071A (en) * 2002-08-29 2005-01-01 Activbiotics Inc Methods and reagents for treating infections of clostridium difficile and diseases associated therewith
AU2004308399A1 (en) * 2003-12-23 2005-07-14 Activbiotics, Inc. Rifamycin analogs and uses thereof
JP2009526069A (ja) * 2006-02-08 2009-07-16 バイオシネクサス インコーポレーティッド 細菌胞子の中和
GB0714030D0 (en) * 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
US8518873B2 (en) * 2007-09-12 2013-08-27 The Medicines Company Method of inhibiting clostridium difficile by administration of oritavancin

Also Published As

Publication number Publication date
EP2195004A4 (en) 2011-12-28
BRPI0816662A2 (pt) 2017-06-13
CN102316885A (zh) 2012-01-11
US9220749B2 (en) 2015-12-29
EP2195004B1 (en) 2015-04-01
ES2535928T3 (es) 2015-05-19
US20100311646A1 (en) 2010-12-09
AU2008298987A1 (en) 2009-03-19
EA017564B1 (ru) 2013-01-30
JP2010539179A (ja) 2010-12-16
US20140100157A1 (en) 2014-04-10
CA2699550A1 (en) 2009-03-19
EP2195004A1 (en) 2010-06-16
US20130310308A1 (en) 2013-11-21
AU2008298987B2 (en) 2013-12-05
US8518873B2 (en) 2013-08-27
US8629100B2 (en) 2014-01-14
EA201000383A1 (ru) 2010-10-29
CA2699550C (en) 2020-08-18
WO2009036121A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
JP5591112B2 (ja) オリタバンシンの投与によってクロストリジウム・ディフィシレを抑制する方法
US11529361B2 (en) Halogenated salicylanilides for treating Clostridium infections
ES2884673T3 (es) Oritavancina para inhibir y tratar biopelículas
AU2009285564B2 (en) Methods of treatment using single doses of oritavancin
KR20010022237A (ko) 리소스타핀을 단독 또는 항생제와의 조합으로 포함하는포도상구균 감염 치료용 약제학적 조성물
CA2664444C (en) Use of oritavancin for prevention and treatment of anthrax
CN117442739A (zh) 一种联合复方药在病原细菌持留感染治疗中的应用
WO2015031579A2 (en) Methods for treating bacterial infections using oritavancin and polymyxins
BRPI0816662B1 (pt) Método in vitro para inibir crescimento de esporo de c. difficile
AU2013202360B2 (en) Methods of treatment using single doses of oritavancin
RU2813568C2 (ru) Антибактериальные композиции

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20101116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110901

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130604

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130611

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20130805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130805

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131022

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140117

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140708

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140729

R150 Certificate of patent or registration of utility model

Ref document number: 5591112

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250